Skip to main content

Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis

SellVALUE-TRAP 3/5Moderate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Sell if holding. Engine safety override at $36.27: Risk below floor (2.9 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.6/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 1.92; Negative price momentum.

Indivior Pharmaceuticals is the market leader in long-acting injectable medications for opioid use disorder, with SUBLOCADE (monthly buprenorphine injection) and SUBOXONE Film as its core products, sold primarily in the US which accounted for 85% of net revenues in 2025.... Read more

$36.27+21.1% A.UpsideScore 6.6/10#2 of 29 Drug Manufacturers - Specialty & Generic
QualityF-score5 / 9FCF yield1.02%
Stop $34.40Target $44.80(analyst − 13%)A.R:R 1.7:1
Analyst target$51.50+42.0%6 analysts
$44.80our TP
$36.27price
$51.50mean
$59

Sell if holding. Engine safety override at $36.27: Risk below floor (2.9 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.6/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 1.92; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 6.6/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Val8.1Qual6.7Grw8.7Mom3.5Sent7.4Ins5.1Peer6.6Tech5.7Risk2.96.6OVERALL

Recent Developments — Indivior Pharmaceuticals, Inc.

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
No bull case signals
Risks
Risk below floor (2.9 < 3.0)
Value-trap signals (3/5): Margin compression (op margin -65.5%), Material insider selling (41 sells, 0.16% of cap), Negative free cash flow

Key Metrics

P/E (TTM)18.7
P/E (Fwd)9.3
Mkt Cap$4.3B
EV/EBITDA10.1
Profit Mgn19.5%
ROE—
Rev Growth19.2%
Beta1.20
DividendNone
Rating analysts12

Quality Signals

Piotroski F5/9MoatNarrow

Options Flow

P/C1.92bearish
IV66%elevated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Risk profile below the gate floor. Component breakdown shows what dragged the score down.static

Put Call
0.6
Volatility
1.1
Implied Vol
2.3
Days To Cover
3.2
Short Interest
3.8
Beta
6.2
Elevated put/call: 1.92High IV: 66%

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Obv
1.0
Volume
2.5
Rsi
5.0
Ma Position
9.0
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 3.5<4.5A.R:R 1.7 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 79d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
63 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $32.34Resistance $41.00

Price Targets

$34
$45
A.Upside+23.5%
A.R:R1.7:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Risk below floor (2.9 < 3.0)
! Value-trap signals (3/5): Margin compression (op margin -65.5%), Material insider selling (41 sells, 0.16% of cap), Negative free cash flow
! Momentum score 3.5/10 — below 4.5 minimum

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-08-06 (79d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is INDV stock a buy right now?

Sell if holding. Engine safety override at $36.27: Risk below floor (2.9 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.6/10 and A.R:R 1.7:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Elevated put/call ratio: 1.92; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $34.40. Score 6.6/10, moderate confidence.

What is the INDV stock price target?

Take-profit target: $44.80 (+21.1% upside). Prior stop was $34.40. Stop-loss: $34.40.

What are the risks of investing in INDV?

Risk below floor (2.9 < 3.0); Value-trap signals (3/5): Margin compression (op margin -65.5%), Material insider selling (41 sells, 0.16% of cap), Negative free cash flow.

Is INDV overvalued or undervalued?

Indivior Pharmaceuticals, Inc. trades at a P/E of 18.7 (forward 9.3). TrendMatrix value score: 8.1/10. Verdict: Sell.

What do analysts say about INDV?

12 analysts cover INDV with a consensus score of 4.3/5. Average price target: $52.

What does Indivior Pharmaceuticals, Inc. do?Indivior Pharmaceuticals is the market leader in long-acting injectable medications for opioid use disorder, with...

Indivior Pharmaceuticals is the market leader in long-acting injectable medications for opioid use disorder, with SUBLOCADE (monthly buprenorphine injection) and SUBOXONE Film as its core products, sold primarily in the US which accounted for 85% of net revenues in 2025. SUBLOCADE represented 69% of total net revenues in 2025, up from 64% in 2024. The company redomiciled from the UK to the US in January 2026.

Related stocks: NBIX (Neurocrine Biosciences, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · BHC (Bausch Health Companies Inc.) · COLL (Collegium Pharmaceutical, Inc.) · LNTH (Lantheus Holdings, Inc.)